UK’s first commercial synthetic biology foundry begins production
SynbiCITE’s has begun production at the UK’s first commercial synthetic biology foundry.
The site provides automated end-to-end design, construction and validation of synthetic biologic components combined with a unique open access and sharing software which allows researchers to speed-up innovation by sharing their biodesign protocols with different labs around the world.
Dr Stephen Chambers, CEO, describes the aims of the SynbiCITE Foundry: “To accelerate the translation of synthetic biology R&D into the marketplace. The Foundry has been created and built to operate as a ‘cloud lab’ to support synthetic biologists across the UK and is for everyone in the business of synthetic biology and who can use synthetic biology in their business.
“These remote users send their biodesigns to the Foundry, which executes the work and delivers the data or prototype to the biodesigner once the work is complete. The Foundry provides a ‘maker space’ for entrepreneurial scientists looking to commercialise their research, ready access to state-of-the-art automation for SMEs, and is a facility for large and small companies to explore the enormous potential of synthetic biology.”
AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics …
Prominent industry player Boehringer Ingelheim has unveiled plans to invest €230 million into the construction …